A systematic review of community based hepatitis C treatment by Amanda J. Wade et al.
RESEARCH ARTICLE Open Access
A systematic review of community based
hepatitis C treatment
Amanda J. Wade1,2*, Vanessa Veronese1,2, Margaret E. Hellard1,2,3 and Joseph S. Doyle1,3,4
Abstract
Background: Hepatitis C virus (HCV) treatment uptake globally is low. A barrier to treatment is the necessity to attend
specialists, usually in a tertiary hospital. We investigate the literature to assess the effect of providing HCV treatment in
the community on treatment uptake and cure.
Methods: Three databases were searched for studies that contained a comparison between HCV treatment uptake or
sustained virologic response (SVR) in a community site and a tertiary site. Treatment was with standard interferon with
or without ribavirin, or pegylated interferon and ribavirin. A narrative synthesis was conducted.
Results: Thirteen studies fulfilled the inclusion criteria. Six studies measured treatment uptake; three demonstrated an
increase in uptake at the community site, two demonstrated similar rates between sites and one demonstrated
decreased uptake at the community site. Nine studies measured SVR; four demonstrated higher SVR rates in the
community, four demonstrated similar SVR rates, and one demonstrated inferior SVR rates in the community
compared to the tertiary site.
Conclusion: The data available supports the efficacy of HCV treatment in the community, and the potential for
community based treatment to increase treatment uptake. Whilst further studies are required, these findings
highlight the potential benefit of providing community based HCV care – benefits that should be realised as
interferon-free therapy become available.
(PROSPERO registration number CRD42015025505).
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Background
Each year in Australia less than 2 % of people infected
with hepatitis C virus (HCV) are treated and globally
treatment uptake rates are similarly low [1]. Barriers to
HCV treatment include; difficulty in accessing a treat-
ment service, not being offered treatment once in a
treatment service and toxic pegylated interferon based
treatment with poor efficacy [2–5]. Stigma is also a sig-
nificant barrier to treatment in health care settings [6].
Fortunately the HCV treatment landscape is changing;
pegylated interferon, ribavirin and protease inhibitor
regimens of 6–12 months duration, which generate serious
adverse effects in about 10 % of people and achieve cure in
only 70 % are being replaced by all oral, well tolerated
interferon free, direct acting antiviral (DAA) therapy, often
for 12 weeks duration, with cure in more than 95 % [7, 8].
Although treatment tolerability and efficacy as a barrier to
HCV treatment has been overcome, in the vast majority of
countries HCV antiviral costs remain prohibitive. For DAA
therapy to have maximum impact on the HCV epidemic, it
must be affordable and accessible. To date, in most de-
veloped and many developing countries specialist phy-
sicians have provided HCV treatment, usually from
tertiary hospital outpatient clinics. Such clinics often
have rigid appointment scheduling and do not always
provide multidisciplinary care. The reassuring safety
profile and high efficacy of DAA therapy means HCV
treatment could now be provided in a diverse range of
clinical settings. HCV treatment could be provided in
community-based clinics, including opioid substitution
therapy (OST) clinics or using telehealth, with a variety
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of service providers including nurses, general practitioners
and specialists. Increasing treatment accessibility may sig-
nificantly improve HCV treatment uptake and cure, but a
key issue is a lack of quality information about which
model of care is most efficacious.
The Australian government has recently made a land-
mark decision to fund DAA therapy for every Australian
infected with hepatitis C from 1st March 2016 [9]. In
addition, a new model of care will be implemented in order
to facilitate access to treatment. General practitioners will
be able to prescribe DAA, albeit after authorization from a
specialist [10]. As the new Australian model of care un-
folds, it is timely to reflect upon the available evidence re-
garding hepatitis C treatment in the community.
To gain data that may inform HCV service delivery
policy, we reviewed the literature to compare treatment
uptake rates in community based treatment services
with conventional tertiary services, and to compare sus-
tained virological response (SVR) outcomes in patients
treated with standard interferon with or without ribavirin,
or pegylated interferon and ribavirin, in the community
with patients treated in conventional tertiary settings.
Methods
Published research was scanned by formal searches of
three electronic databases (Medline, EMBASE and
CINAHL) from January 2000 to July 2015. Search terms
included “hepatitis C”, “antiviral agents”, “patient care
management” and “healthcare delivery”. The full search
strategy is detailed in the Additional file 1. Citations
were screened and evaluated using the established inclu-
sion and exclusion criteria at the abstract level by two
operators (AW and VV), and relevant studies were re-




(i) people with chronic HCV infection and;
(ii) provision of treatment for hepatitis C in the
community and;
(iii)comparison with tertiary based services and;
(iv)measuring and reporting either treatment uptake
or SVR outcomes.
Treatment could include pegylated interferon and riba-
virin, with or without DAA or interferon-free. Health care
provider could be a specialist or general practitioner or
nurse; the use of telehealth was permitted.
Exclusion criteria were defined as:
(i) treatment of custodial populations or;
(ii) treatment of HIV-HCV co-infected populations or;
(iii)treatment of children or;
(iv)treatment in residential facilities
(i.e. inpatient rehabilitation) or;
(v) modeling studies or;
(vi)papers assessing patient or practitioner knowledge
or attitudes or;
(vii)papers published before 2000 because interferon
ribavirin combination therapy was only licensed in
1998 and antiviral treatment was exclusively
delivered in tertiary care.
1.2.Definitions and end-points
A community service was defined as a medical
service that was not a tertiary hospital or academic
facility, including primary care clinics that may
provide opiate substitution therapy (OST) and
private practice. Treatment uptake was defined
as proportion of HCV infected patients at service
that received a prescription for HCV treatment.
Cure was defined as sustained virologic response
(SVR) at week 12 or 24 post cessation or
completion of HCV treatment.
1.3. Study selection
Using inclusion and exclusion criteria, identified
abstracts were assessed for relevance by two
researchers (AW and VV). Variations in citation
assessment were resolved by a third reviewer (JD).
Full text papers were then retrieved for review. If
further data were required to classify a full text
paper the authors were contacted. The following
information was obtained for each article; authors,
year of publication, country of origin, number of
subjects, healthcare delivery structure, treatment
uptake rate, SVR rate. For studies that measured
SVR rate the following additional data was extracted:
proportion with genotype 1 infection, proportion
with HIV co-infection, prior treatment history and
proportion with advanced fibrosis.
A narrative review of the included studies was per-
formed. This review is registered with the PROSPERO
database (registration number CRD42015025505).
Results
The flow diagram of the study analysis is shown in Fig. 1.
The search generated 1499 citations, 413 duplicates were
then deleted. Of the remaining 1086 citations, 967 were
excluded based on the abstract. Full text articles were re-
trieved for 119 citations. A further 8 articles were
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included after citations searching. Thirteen of the 127
articles fulfilled the inclusion criteria. A summary of data
from included articles is shown in Table 1, below.
Five of the included studies were from the US, two
were from Taiwan and there was one study each from
Australia, New Zealand, Greece, France, Germany and
Canada. The interventions to provide treatment in the
community were diverse and included telehealth and
treatment provision from primary care clinics, opioid
substitution therapy (OST) clinics or needle exchange
programs. Treatment consisted of pegylated interferon
and ribavirin in all studies but for Moriarty [11] and Gigi
[12], in which standard interferon with or without riba-
virin was also included.
Studies which measured treatment uptake only
(see Table 2)
Two studies investigated the outcome of treatment
provision in opioid substitution clinics, and had different
results. Moussalli et al. noted an increase in treatment
uptake when provided at an OST clinic. Before treat-
ment was available in the OST clinic two of 337 patients
had commenced treatment for HCV. After treatment
was made available in the OST clinic 85 patients com-
menced therapy, and of those patients 37 (44 %) achieved
an SVR [13]. However, in a retrospective cohort study in
Greece, only 17 of 204 HCV antibody positive patients
(8 %) commenced treatment in an OST setting, compared
to 276 of 643 patients (43 %) in a tertiary liver unit [12].
Of note, few HCV antibody positive patients in the OST
clinic had HCV RNA testing performed - 33 of 204, of
which 28 were positive. In comparison, 498 of the 643
HCV antibody positive patients in the tertiary liver unit
were known to be HCV RNA positive.
A retrospective study of treatment uptake in a needle and
syringe exchange program (NSEP) centre in New Zealand
found of 51 HCV infected patients, four commenced treat-
ment at the needle exchange centre, whilst only one patient
commenced treatment at the hospital [11].
A large retrospective study in the US demonstrated that
treatment uptake in primary care clinics 251 of 1929 pa-
tients (13 %) was similar to treatment uptake in specialist
clinics 3537 of 24,853 (14 %) [14].
Studies which measured treatment outcome only
(see Table 3)
Three cohort studies compared SVR rates obtained by
standard care in a tertiary hospital with SVR rates ob-
tained using telehealth (video-conferencing) to popula-
tions with poor access to specialist care i.e. in rural or
remote areas, or prison. A large prospective study in the
US demonstrated no difference in SVR between patients
treated in tertiary care and patients treated by their pri-
mary care clinician with telehealth support (58 % in both
groups) [15]. A smaller retrospective study in the US
demonstrated similar results, with 43 % of tertiary pa-
tients obtaining an SVR compared to 55 % patients
treated via telehealth [16]. A retrospective Australian
study found 72 % of telehealth treated patients had an
SVR compared to 59 % of tertiary treated patients [17].
All three studies demonstrate SVR rates achieved in tele-
health care were similar or higher when compared to
SVR rates achieved in tertiary care.
Chen et al., performed a study in which patients se-
lected treatment delivered via telephone consultations
Fig. 1 Flow diagram of study analysis
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provided from a health communication center, or treat-
ment delivered conventionally in a hospital outpatient
clinic, and detected no difference in SVR outcomes [18].
Three observational studies examined SVR outcomes
of community based treatment. Jou retrospectively ana-
lysed results from a randomized control drug trial ac-
cording to treatment site. SVR outcome were the same
in the academic (40 %) and the community (39 %) sites
[19]. Niederau also found similar SVR outcomes between
treatment provided in a hospital with 290 of 621 patients
(47 %) attaining SVR, and 1744 of 3778 patients (46 %)
attaining SVR in private practice [20]. However, in an ob-
servational study in Canada lower rates of SVR were seen
in community settings 120 of 250 patients (48 %), when
compared to academic centres, 79 of 133 patients (59 %)
[21]. Further analysis demonstrated the difference was due
to lower SVR rates in patients infected with genotype 1
treated in the community.
Studies which measured treatment uptake and outcome
(see Tables 2 and 3)
Bruce et al. conducted a randomized clinical trial in
which subjects on methadone in an OST clinic were
randomized to receive modified directly observed treat-
ment at the OST clinic or standard of care therapy at a
tertiary liver clinic. Subjects treated at the OST clinic
had directly observed therapy (DOT) for methadone,
pegylated interferon and morning ribavirin doses, but
self administered evening ribavirin. All 12 patients ran-
domized to the OST clinic started treatment and six of
eight patients (75 %) eligible to be assessed for SVR
achieved SVR. In comparison four of the nine patients
(44 %) randomized to standard of care commenced
treatment and one of three patients (33 %) eligible to be
assessed for SVR achieved an SVR [22].
A small Taiwanese study showed similar treatment up-
take rates with tertiary care, four of eighteen patients
Table 1 Summary of included studies
Study Year Country Design Intervention Facility n Rx uptake SVR
n (%) n (%)
Arora 2011 USA Prospective cohort study
of treatment outcome
Telehealth to support primary
care (in community and prison)
Tertiary 146 84/146 (58)
Primary total (Prisoners) 261 (106) 152/261 (58)
Bruce 2012 USA Randomised controlled trial
of treatment uptake
and outcome
Directly observed therapy in
OST clinic vs self administered
treatment in tertiary clinic
Tertiary 9 4/9 (44) 1/4 (33)
Primary 12 12/12 (100) 6/12 (75)
Chen 2014 Taiwan Prospective cohort study
of treatment outcome
Telecare Tertiary 150 99/150 (66)
Telecare 148 102/148 (69)
Gigi 2013 Greece Retrospective cohort study
of treatment uptake
Rx in OST clinic Tertiary 643 Ab+ 276/643 (43)
Primary 204 Ab+ 17/204 (8)
Jou 2013 USA Retrospective cohort study
of treatment outcome
Analysis of data by Rx site Academic 1905 760/1905 (40)
Community 1165 455/1165 (39)
Kramer 2010 USA Retrospective cohort study
of treatment uptake
Specialist clinic 24,853 3537 (14)
Primary Care clinic 1929 251 (13)
Kuo 2015 Taiwan Prospective cohort study
of treatment uptake
and outcome
Rx in community Pre intervention 18 4/18 (22) 2/4 (50)
Post intervention 3/16 (19) 3/3 (100)
Moriarty 2001 New Zealand Observational study
of treatment uptake
Rx co-located at NSP site Tertiary 51 1 (2)
Primary 4 (8)
Moussalli 2010 France Observational study
of treatment uptake
Rx in OST clinic Pre intervention 337 2/337 (0.6)
Post intervention 85/335 (25) 37/85 (44)
Myers 2011 Canada Observational study
of treatment outcomes
Academic 133 79/133 (59)
Community 250 120/250 (48)
Nazareth 2013 Australia Retrospective cohort study
of treatment outcomes
Telehealth Tertiary 528 311/528 (59)
Telehealth 50 36/50 (72)
Niederau 2014 Germany Prospective cohort study
of treatment outcome
Analysis of adherence to
guidelines by Rx site
Hospital based 621 290/621 (47)
Private practice 3778 1744/3778 (46)
Rossaro 2013 USA Retrospective cohort study
of treatment outcomes
Telehealth Tertiary 40 16/37 (43)
Telehealth 40 21/38 (55)
Rx treatment, OST opioid substitution therapy, Ab + HCV antibody positive
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(22 %) compared to three of 16 patients (19 %) commen-
cing treatment when it was made available in the com-
munity [23]. SVR was achieved in two of four patients
(50 %) in the tertiary facility and three of three patients
(100 %) in the community facility.
Discussion
This systematic review has identified publications, which
contain a comparison between HCV treatment uptake
rates or SVR outcomes in community and tertiary treat-
ment services. Of the thirteen publications included,
only one was a randomized controlled trial and the re-
mainder were observational studies. The interventions
that resulted in HCV treatment provision in the com-
munity were diverse, and included; telehealth, integrated
HCV services in OST clinics or NSEP services, private
medical practice and outreach services staffed by specialists
or nurses.
Of the six studies that measured treatment uptake as
an outcome (see Table 2), three demonstrated an in-
crease in uptake at the community site [11, 13, 22].
Interestingly, two of these studies were conducted in
OST clinics, and the third in a NSEP service. Two studies
demonstrated similar treatment uptake rates between the
community and tertiary services [14, 23]. The large study
by Kramer et al. investigated the treatment uptake within
the Veterans Affairs Healthcare in the United States ac-
cording to whether treatment was provided from a pri-
mary care provider clinic or a specialist clinic. It is not
known what proportion of the primary care provider
clinics may have been OST providers as well. One study
demonstrated decreased treatment uptake at the commu-
nity site [12]. The authors attributed this difference to a
difficulty in collaboration between OST staff and hospital
based specialists.
The factors contributing to increased treatment uptake
in the community sites varied according to the study;
provision of non invasive fibrosis assessment (Fibrotest-
Actitest) (Mousalli), multidisciplinary services (Mousalli,
Moriarty, Bruce), modified directly observed therapy
(Bruce) and gaining trust (Moriarty), led to improved
management of HCV in the community setting.
Of the nine studies that measured SVR as an outcome
(see Table 3), four demonstrated higher SVR rates in the
community group [16, 17, 22, 23]. Possible reasons for
this include that the community services were more
Table 2 Summary of studies which investigated treatment uptake
Study Study population and policy for
initiating treatment
(if included in publication)




Bruce HCV infection +/− HIV
Attendance at OST clinic
Rx according to published
guidelines and the
same in both facilities








Gigi HCV antibody positive
Attended Liver clinic or OST clinic
Policy for Rx initiation not published
Tertiary 643 0 Nil 276 (43)
Primary 204 100 Nil 17 (8)
Kramer HCV infection
Designated Primary Care Provider
Majority of care from one Veterans
Affairs facility
Rx indicated if more than portal
fibrosis and no
contraindications (including no
active illicit drug use)
Specialist clinic 24,853 N/P N/P 3537 (14)
Primary clinic 1929 N/P N/P 251 (13)
Kuo HCV antibody positive
Participation in screening program
Pre-intervention Rx if: ALT >40 (once)
and > F1 or HCV RNA positive
Post intervention Rx if ALT >80 (twice)
and > F1
Pre intervention 18 N/P N/P 4 (22)
Post intervention N/P N/P 3 (19)
Moriarty HCV infection
Attendance at outreach clinic
Policy for Rx initiation not published
Tertiary 51 N/P N/P 1 (2)
Primary N/P N/P 4 (8)
Moussalli HCV infection
Attendance at OST Primary
healthcare facility
Rx if > F2 fibrosis
Pre-intervention 337 N/P N/P 2 (0.6)
Post intervention N/P N/P 85 (25)
OST opioid substitution therapy, N/P not provided, Rx treatment
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convenient for the patients and offered a “one stop shop”
where multiple needs could be met, or that HCV treat-
ment was integrated into a developed patient-provider re-
lationship. Another explanation is that the availability of
multidisciplinary services may have helped mitigate fac-
tors associated with poor adherence or SVR outcomes in
PWID such as unstable housing, poor social functioning
and ongoing drug use [24]. Four studies demonstrated
similar outcomes between the two treatment settings
[15, 18–20]. One study from Canada in which 250 pa-
tients were treated in the community and 133 in an
academic centre, demonstrated lower SVR rates in pa-
tients treated in the community [21]. The difference was
due to SVR outcomes in genotype one patients only.
Patient characteristics including level of fibrosis, rates of
dose modification and treatment cessation for genotype
one infected patients were similar in the community and
academic sites, and an explanation for the difference in
SVR between treatment sites was not apparent.
Modelling studies indicate that treatment uptake is the
major limiting factor to substantial reductions in disease
burden. Current treatment rates in Australia of 3 per
1000 PWID annually would need to be scaled up to 40
per 1000 PWID annually to halve HCV prevalence by
2030. [25]. The advent of DAA therapy has made the
elimination of HCV a tangible concept since treatment
is simple and well tolerated, but for this to be achieved a
significant change in service delivery would be required,
and has been undertaken.
Nine of ten studies reporting SVR outcomes demon-
strated similar or superior SVR rates were achieved in
the community. Further, findings in this review suggest
that decentralising HCV services and providing HCV
treatment in the community, particularly OST clinics,
may increase treatment uptake. Numerous cohort studies
conducted in OST clinics indicate that HCV treatment in
this setting can be successful, even in the peginterferon
based treatment era [19, 26, 27]. The key components of
successful HCV treatment delivery in the community
need to be identified, to inform policy and ensure that in-
tegrated services are adequately resourced.
This review was limited by the lack of published data
that compares outcomes of HCV treatment delivered in
the community with treatment delivered in conventional
tertiary settings. Some studies included in the review
have a small number of participants and therefore lack
statistical power. There was only one small randomised
controlled trial comparing community and tertiary based
treatment, and this study also provided DOT to the pa-
tients in the community arm, rendering the relative contri-
bution of both interventions difficult to assess. This review
investigated interferon based HCV treatment and therefore
Table 3 Summary of trials which investigated treatment outcome








Prior treatment Fibrosis assessment Fibrosis result SVR
Mean or % n (%)
Arora Tertiary 146 45 45 57 0 Naive APRI 0.938 84 (58)
Telehealth 261 42 73 56 0 0.935 152 (58)
Bruce Tertiary 9 43 67 67 (G1&4) 3 (33) N/P Biopsy (G1 only) F4 33 % 1 (33)
Primary 12 40 42 67 (G1&4) 3 (25) F4 25 % 6 (75)
Chen Tertiary 150 52 N/P 58 0 Naive N/P 99 (66)
Primary 148 47 N/P 61 0 N/P 102 (69)
Jou Academic 1905 48 59 100 0 Naive Biopsy F3/4 10 % 760 (40)
Community 1165 47 61 100 0 F3/4 11 % 455 (39)
Kuo Preintervention 18 57 33 N/P N/P N/P N/P 2 (50)
Post intervention 3 (100)
Myers Academic 133 46 70 49 0 Naïve & experienced Biopsy F4 14 % 79 (59)
Community 250 46 64 55 0 F4 10 % 120 (48)
Nazareth Tertiary 528 43 65 N/P N/P Naïve & experienced Biopsy or Hepascore F4 19 % 311 (59)
Telehealth 50 46 50 60 N/P Hepascore F4 20 % 36 (72)
Niedaerau Hospital based 621 N/P N/P 100 N/P N/P N/P 290 (47)
Private practice 3778 N/P N/P 100 N/P N/P 1744 (46)
Rossaro Tertiary 40 54 55 65 0 Naive Biopsy F4 45 % 16 (43)
Telehealth 40 51 48 65 0 F4 28 % 21 (55)
N/P not provided
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the findings may not be applicable to HCV treatment with
DAA. A large randomised controlled trial addressing the
effect of community provision of HCV DAA treatment –
the Prime Study based in Melbourne, Australia – is under-
way (clinicaltrials.gov NCT02555475). It is likely that any
treatment outcome difference between hospital and com-
munity care may become less pronounced as treatment
becomes easier with DAA therapy.
Conclusion
In conclusion, this review demonstrates that the limited
data available supports the safety of peginterferon based
HCV treatment in the community, and the potential for
community based treatment to increase treatment up-
take. The paucity of high quality data available to assess
the effect of HCV treatment in the community on HCV
treatment uptake is striking. This variable is a key com-
ponent in the hepatitis C cascade of care, and further
studies are warranted to clarify how best to structure
HCV service delivery in the era of DAA.
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